Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

Recruiting Phase 2 Phase 3 Interventional Study
Clostridium Difficile Infection Vancomycin Resistant Enterococci Infection
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Prevention
Participants needed
176 (estimated)
Sponsor
Riverside University Health System Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the drug in this setting. The main questions the trial aims to answer are: * Does oral vancomycin lower the rate of C.diff …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Must meet all 3 criteria: * Adults aged 18 years and older. * Receiving ≥ 72 hours of a systemic antibiotic during index hospitalization. * Admitted ≥ 72 hours into their index hospitalization. 2. And must meet 2 additional of the following high-risk criteria * …
Contacts

Suman Thapamagar, MD

9514864000

suman.thapamagar@ruhealth.org

CONTACT

Brian Phan, PharmD

9514864000

b.phan@ruhealth.org

CONTACT